|
|
Previous Article | Table of Contents | Next Article 
Blood, 15 October 2000, Vol. 96, No. 8, pp. 2849-2855
NEOPLASIA
Arsenic-interferon- -triggered apoptosis in HTLV-I transformed
cells is associated with Tax down-regulation and reversal of
NF- B activation
Marwan E. El-Sabban,
Rihab Nasr,
Ghassan Dbaibo,
Olivier Hermine,
Nour Abboushi,
Frédérique Quignon,
Jean Claude Ameisen,
Françoise Bex,
Hugues de
Thé, and
Ali Bazarbachi
From the Departments of Human Morphology, Internal
Medicine, Biochemistry, and Pediatrics, Faculty of Medicine, American
University of Beirut, Beirut, Lebanon; CNRS URA 1461 and Department of
Hematology, Necker Hospital, Paris, France; UPR 9051 CNRS Laboratoire
associé No. 11 du comité de Paris de la Ligue contre le
Cancer, conventionné par l'Université Paris VII,
Hôpital St Louis, Paris, France; INSERM CJF 9701, Hôpital
Bichat, Paris, France; and Departement de Biologie Moléculaire,
Université Libre de Bruxelles, Brussels, Belgium.
Human T-cell lymphotropic virus type I (HTLV-I)-associated
adult T-cell leukemia/lymphoma (ATL) is a malignancy of mature activated T cells resistant to conventional chemotherapy. The viral
transactivator protein Tax plays a critical role in
HTLV-I-induced transformation and apoptosis resistance by inducing
I B- degradation, resulting in the activation of the
NF- Bpathway. In these HTLV-I-transformed cells, arsenic trioxide
(As) and interferon (IFN)- synergize to induce cell cycle arrest and
apoptosis. We demonstrate that cell death induction is only partly
dependent upon caspase activation and is not associated with modulation
of bcl-2, bax, or p53 expression. However, combined As and IFN induce
the degradation of Tax, associated with an up-regulation of I B-
resulting in a sharp decrease in RelA DNA binding nuclear factor
(NF)- B complexes because of the cytoplasmic retention of RelA. Taken
the role of Tax in HTLV-I-induced transformation, its down-regulation
probably accounts for cell death induction through inactivation of the
NF- B pathway. Such specific targeting of the viral oncoprotein by
As-IFN treatment, reminiscent of As targeting of promyelocytic
leukemia/retinoic acid receptor- in acute promyelocytic
leukemia, provides strong rational for combined As-IFN therapy in ATL patients.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
G P Taylor
Molecular aspects of HTLV-I infection and adult T-cell leukaemia/lymphoma
J. Clin. Pathol.,
December 1, 2007;
60(12):
1392 - 1396.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. S. Dbaibo, Y. Kfoury, N. Darwiche, S. Panjarian, L. Kozhaya, R. Nasr, M. Abdallah, O. Hermine, M. El-Sabban, H. de The, et al.
Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity
Haematologica,
June 1, 2007;
92(6):
753 - 762.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Brown, M. Bellon, and C. Nicot
Emodin and DHA potently increase arsenic trioxide interferon-{alpha}-induced cell death of HTLV-I-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1
Blood,
February 15, 2007;
109(4):
1653 - 1659.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Mahieux
HTLV-I and AZT: die another day
Blood,
August 1, 2006;
108(3):
785 - 786.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Datta, M. Bellon, U. Sinha-Datta, A. Bazarbachi, Y. Lepelletier, D. Canioni, T. A. Waldmann, O. Hermine, and C. Nicot
Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence
Blood,
August 1, 2006;
108(3):
1021 - 1029.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X.-F. Che, C.-L. Zheng, S. Owatari, M. Mutoh, T. Gotanda, H.-C. Jeung, T. Furukawa, R. Ikeda, M. Yamamoto, M. Haraguchi, et al.
Overexpression of survivin in primary ATL cells and sodium arsenite induces apoptosis by down-regulating survivin expression in ATL cell lines
Blood,
June 15, 2006;
107(12):
4880 - 4887.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Okudaira, M. Tomita, J.-N. Uchihara, T. Matsuda, C. Ishikawa, H. Kawakami, M. Masuda, Y. Tanaka, K. Ohshiro, N. Takasu, et al.
NIK-333 inhibits growth of human T-cell leukemia virus type I-infected T-cell lines and adult T-cell leukemia cells in association with blockade of nuclear factor-{kappa}B signal pathway.
Mol. Cancer Ther.,
March 1, 2006;
5(3):
704 - 712.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Rizvi, A. M. Evens, M. S. Tallman, B. P. Nelson, and S. T. Rosen
T-cell non-Hodgkin lymphoma
Blood,
February 15, 2006;
107(4):
1255 - 1264.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. M. B. Kerbauy, V. Lesnikov, N. Abbasi, S. Seal, B. Scott, and H. J. Deeg
NF-{kappa}B and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs)
Blood,
December 1, 2005;
106(12):
3917 - 3925.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Sinha-Datta, I. Horikawa, E. Michishita, A. Datta, J. C. Sigler-Nicot, M. Brown, M. Kazanji, J. C. Barrett, and C. Nicot
Transcriptional activation of hTERT through the NF-{kappa}B pathway in HTLV-I-transformed cells
Blood,
October 15, 2004;
104(8):
2523 - 2531.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.-J. Jeong, M. Radonovich, J. N. Brady, and C. A. Pise-Masison
HTLV-I Tax induces a novel interaction between p65/RelA and p53 that results in inhibition of p53 transcriptional activity
Blood,
September 1, 2004;
104(5):
1490 - 1497.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Mohapatra, B. Chu, S. Wei, J. Djeu, P. K. Epling-Burnette, T. Loughran, R. Jove, and W. J. Pledger
Roscovitine Inhibits STAT5 Activity and Induces Apoptosis in the Human Leukemia Virus Type 1-Transformed Cell Line MT-2
Cancer Res.,
December 1, 2003;
63(23):
8523 - 8530.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Mathas, A. Lietz, M. Janz, M. Hinz, F. Jundt, C. Scheidereit, K. Bommert, and B. Dorken
Inhibition of NF-{kappa}B essentially contributes to arsenic-induced apoptosis
Blood,
August 1, 2003;
102(3):
1028 - 1034.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Nasr, A. Rosenwald, M. E. El-Sabban, B. Arnulf, P. Zalloua, Y. Lepelletier, F. Bex, O. Hermine, L. Staudt, H. de The, et al.
Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells
Blood,
June 1, 2003;
101(11):
4576 - 4582.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z.-y. Wang
Ham-Wasserman Lecture: Treatment of Acute Leukemia by Inducing Differentiation and Apoptosis
Hematology,
January 1, 2003;
2003(1):
1 - 13.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Hayashi, T. Hideshima, M. Akiyama, P. Richardson, R. L. Schlossman, D. Chauhan, N. C. Munshi, S. Waxman, and K. C. Anderson
Arsenic Trioxide Inhibits Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment
Mol. Cancer Ther.,
August 1, 2002;
1(10):
851 - 860.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. H. Miller Jr., H. M. Schipper, J. S. Lee, J. Singer, and S. Waxman
Mechanisms of Action of Arsenic Trioxide
Cancer Res.,
July 15, 2002;
62(14):
3893 - 3903.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. E. El-Sabban, R. A. Merhi, H. A. Haidar, B. Arnulf, H. Khoury, J. Basbous, J. Nijmeh, H. de The, O. Hermine, and A. Bazarbachi
Human T-cell lymphotropic virus type 1-transformed cells induce angiogenesis and establish functional gap junctions with endothelial cells
Blood,
May 1, 2002;
99(9):
3383 - 3389.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Mahieux, C. Pise-Masison, A. Gessain, John. N. Brady, R. Olivier, E. Perret, T. Misteli, and C. Nicot
Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage
Blood,
December 15, 2001;
98(13):
3762 - 3769.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. Murgo
Clinical Trials of Arsenic Trioxide in Hematologic and Solid Tumors: Overview of the National Cancer Institute Cooperative Research and Development Studies
Oncologist,
April 1, 2001;
6(90002):
22 - 28.
[Abstract]
[Full Text]
|
 |
|
| |